Chris Buescher's Nexletol scheme

$ESPR Bempedoic Acid ( Nexletol ) and Nexlizet (BA + ezetimibe ) continue to impress cardiologists. The highly esteemed Dr. Nissen:

'I've been doing cardiovascular trials for 30 years and we've never seen a hazard ratio as favorable as this.'

30% reduction in heart attacks

First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET®in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
Read here: bit.ly/3yFLnM8

so excited for NEXLETOL hell yeah

HEADLINE: People who took 'statin-alternative' Nexletol 3 years had '23% lower risk' of heart attack: 13.3% on placebo vs 11.7% on Nexletol. (% who actually benefited: 13.3 minus 11.7 = 1.6% and no difference in mortality.) Nexletol costs $426 a month. Do the math!

NPR: When FDA approved bempedoic acid (Nexletol) in 2020, it was clear that the drug helped lower LDL 'bad' cholesterol.
[There are multiple lipoproteins; one cholesterol. If you read the insipid phrase 'bad cholesterol,' an ignoramus is pushing worthless, cholesterol-lowering

Check out this awesome and smooth color on last year Nexletol paint scheme! Chris Buescher
.
.
.
#NASCAR #nexletol #chrisbuescher #rfkracing #fordmustang

Bempedoic Acid | Therapy | Dyslipidemia

Part A: Bempedoic Acid approval in Europe

📸 1: First-In-Class cholesterol-lowering treatment NILEMDO® (NEXLETOL® in the U.S.) and Its combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), approved in Europe to treat

🚨🚨🚨Exciting news in #CVPrev today!

✅New indications for Bempedoic Acid (NEXLETOL) & of bempedoic acid+ezetimibe(NEXLIZET)

Both indicated to ⤵️the risk of MI & coronary revascularization in those on max tolerated statin) with
CVD or high risk for CVD event
Danielle Belardo, MD

Good news for Neuland Labs.

USFDA has approved Esperion's new label expansions for NEXLETOL (bempedoic acid) & NEXLIZET (bempedoic acid & ezetimibe) for cardiovascular risk reduction

More than 70 million patients to now be eligible for NEXLETOL and NEXLIZET in US

#neulandlabs

wallstreetbets $ESPR $2.38is the most undervalued #biotech wallstreetbets They Two FDA Approved non- #statin medications #nexlizet & #nexletol had label expansion 2 months ago & now is available to 70M+ Americans. Yesterday great label news for partner DSE. 2M scripts expected by 2027 =$50+

Is your practice taking care of patients facing #statin -intolerance? #primarycare

In a long-term study, bempedoic acid (Nexletol) significantly reduced the risk of heart attacks, strokes, and other cardiovascular events (39.9 months). #BempedoicAcid #HeartHealth

Important update for US HCPs on Nexletol and Nexlizet.

#EsperionTherapeuticsInc U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use globenewswire.com/news-release/2…

🌙 AfterHours News
$ESPR - Esperion Therapeutics
U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
Running !
👆 19.2%/ $2.29

🔥 March & April PDUFAs 🔥

Don't miss out! 🗓️
There are still 5+ events upcoming this month...👇

$MRK ⇒ Sotatercept
$AKBA ⇒ Vafseo
$ESPR ⇒ Nexletol & Nexlizet
$REGN ⇒ Odronextamab
$AZN ⇒ Flumist

and buckle up for next month… 🤩
📌 10 PDUFAs in April 🚀
$VNDA ⇒ Fanapt

📣 Busy month for PDUFAs & AdComs in March! 🚀

$VNDA ⇒ HETLIOZ®
$EYEN ⇒ APP13007
$MIRM ⇒ LIVMARLI
$MDGL ⇒ Resmetirom
$BMY ⇒ Breyanzi®
$OPTN ⇒ XHANCE
$ORTX (Kyowa Kirin) ⇒ Libmeldy
$MRK ⇒ Sotatercept
$AKBA ⇒ Vafseo™
$ESPR ⇒ Nexletol & Nexlizet
$REGN ⇒

$ESPR(1.51) up .50 The pharmaceutical company said the FDA approved an updated LDL-cholesterol lowering indication for nexletol and nexlizet to include the treatment of primary hyperlipidemia as a qualifier for existing approved populations.

Advancing an Anti-Cholesterol Drug Compound at the Height of the Pandemic. #BempedoicAcid #Nexletol #Nexlizet Esperion Inc. neulandlabs.com/blog/2023/04/1…

.Esperion Inc. is committed to developing innovative medicines to improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.

To mark the FDA’s approval of expanded indications for NEXLETOL and NEXLIZET, #NasdaqListed $ESPR is ringing the